Join to view full profile
10 Center Dr Rm 12n226Bethesda, MD 20892
Phone+1 301-480-0536
Dr. Apolo is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Andrea Apolo is an oncologist based in Bethesda, MD, specializing in genitourinary and hematologic oncology. She earned her medical degree from the Albert Einstein College of Medicine in 2003, followed by a residency in internal medicine at New York Presbyterian Hospital and a fellowship in hematology and medical oncology at Memorial Sloan Kettering Cancer Center. Since 2010, she has been an investigator and Lasker Scholar at the NIH Clinical Center. Her expertise includes genitourinary cancer, medical oncology, and neoplasm staging. Dr. Apolo has authored many pivotal publications on topics like urothelial carcinoma, renal cell carcinoma, and rare genitourinary tumors. She is involved in clinical trials focusing on treatments for advanced or metastatic genitourinary tumors.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2003 - 2006
Albert Einstein College of MedicineClass of 2003
Certifications & Licensure
NY State Medical License 2006 - 2027
Clinical Trials
- TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma
- Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors Start of enrollment: 2011 Sep 26
- Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy Start of enrollment: 2012 Feb 16
Publications & Presentations
PubMed
- Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications.Can Aydogdu, Laura Bukavina, Liang Cheng, Hikmat A Al-Ahmadie, Omar Alhalabi
European Urology. 2026-06-26 - TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma.Matthew D Galsky, Alexandra Drakaki, Arnab Basu, Bradley McGregor, Jens Bedke
Future Oncology. 2026-05-01 - Upper tract urothelial carcinoma associated with Lynch syndrome.R Chelluri, S Kovell, F Montanaro, E Chandran, A Rouf Banday
Current Opinion in Oncology. 2026-05-01
Authored Content
- Clinical Trial Endpoints in the Adjuvant Setting for Renal Cell Carcinoma and Urothelial Cancer - Andrea Apolo and Pavlos MsaouelOctober 2022
Press Mentions
Novel ADC Combo Shows Efficacy in Phase 2 Bladder Cancer DataMay 31st, 2026- Overall Survival Doubles at 3 Years with EV+P in Metastatic Urothelial CancerMay 30th, 2026
- Atezolizumab Does Not Demonstrate Significant OS Benefit Compared with Chemotherapy in Untreated Locally Advanced or Metastatic Urothelial CancerFebruary 26th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
